首页> 美国卫生研究院文献>other >Phase II Study of the Oral Mek Inhibitor Selumetinib in Advanced Acute Myeloid Leukemia (AML): A University of Chicago Phase II Consortium Trial

【2h】

Phase II Study of the Oral Mek Inhibitor Selumetinib in Advanced Acute Myeloid Leukemia (AML): A University of Chicago Phase II Consortium Trial

机译：口服Mek抑制剂Selumetinib在晚期急性髓样白血病（AML）中的II期研究：芝加哥大学II期财团试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThe clinical relevance of targeting RAS/RAF/MEK/ERK pathway, activated in 70-80% of acute myeloid leukemia (AML) patients, is unknown.

机译：目的未知在70-80％的急性髓细胞性白血病（AML）患者中激活的靶向RAS / RAF / MEK / ERK途径的临床相关性。

著录项

期刊名称 other
作者
Nitin Jain; Emily Curran; Neil M. Iyengar; Ernesto Diaz-Flores; Rangesh Kunnavakkam; Leslie Popplewell; Mark H. Kirschbaum; Theodore Karrison; Harry P. Erba; Margaret Green; Xavier Poire; Greg Koval; Kevin Shannon; Poluru L. Reddy; Loren Joseph; Ehab L. Atallah; Philip Dy; Sachdev P. Thomas; Scott E. Smith; L. Austin Doyle; Walter M. Stadler; Richard A. Larson; Wendy Stock; Olatoyosi Odenike;
展开▼
作者单位

展开▼
年(卷),期 -1(20),2
年度 -1
页码 490–498
总页数 18
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase 2 study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: A university of chicago phase 2 consortium trial [J] . JainN., CurranE., IyengarN.M., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第2期

机译：口服MEK抑制剂selumetinib在晚期急性粒细胞性白血病中的2期研究：芝加哥大学2期财团试验
2. Phase 2 study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: A university of chicago phase 2 consortium trial [J] . JainN., CurranE., IyengarN.M., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第2期

机译：第2阶段研究口腔梅克抑制剂Selumetinib在晚期急性髓性白血病中：芝加哥大学2号联盟审判
3. University of Chicago phase II consortium trial of selumetinib ( MEK MEK i) demonstrates low tolerability and efficacy in relapsed DLBCL [J] . Galanina Natalie, Smith Sonali M., Liao Chuanhong, British Journal of Haematology . 2018,第2期

机译：芝加哥二期第II阶层Selumetinib（MEK MEK i）的联盟审判展示了重复的DLBCL中的低耐受性和功效
4. Analysis of Competing Endogenous RNA Network and Prediction of Prognosis in Acute Lymphoblastic Leukemia Patients of Phase II and III [C] . Jianzhi Deng, Xiaohui Cheng, Yuehan Zhou International Conference on Modelling, Simulation and Big Data Analysis . 2019

机译：竞争内源性RNA网络的分析及III期急性淋巴细胞白血病患者预后预测
5. Part I: Structural and functional insight into the type A CBFbeta-SMMHC protein and acute myeloid leukemia (AML). Part II: Solution structure of the HDGF PWWP domain and implications of its function as a DNA binding domain. [D] . Lukasik, Stephen Michael. 2006

机译：第一部分：对A型CBFbeta-SMMHC蛋白和急性髓细胞性白血病（AML）的结构和功能洞察。第二部分：HDGF PWWP域的溶液结构及其作为DNA结合域的功能的含义。
6. Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (NCI Trial # 6862): Trial results and IL-6 analysis. A study by the DOD Prostate Cancer Clinical Trial Consortium and University of Chicago Phase II Consortium [O] . Deborah Bradley, Dana Rathkopf, Rodney Dunn, -1

机译：vorinostat在晚期前列腺癌患者进展前化学疗法（NCI试验＃6862）：试验结果和IL-6分析。国防部前列腺癌临床试验联盟和芝加哥二期联盟大学的研究
7. Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial [O] . Nitin Jain, Emily Curran, Neil M. Iyengar, 2013

机译：口服梅克抑制剂Selumetinib在晚期急性髓性白血病中的II期研究：芝加哥二期联盟联盟审判

Phase II Study of the Oral Mek Inhibitor Selumetinib in Advanced Acute Myeloid Leukemia (AML): A University of Chicago Phase II Consortium Trial

摘要

著录项

相似文献

相关主题

期刊订阅